Vitamin c and immunotherapy combo trial for lung cancer ends early after just one patient
Disease control
Terminated
This very early trial aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune response against non-small cell lung cancer before surgery. It planned to enroll people with early-stage lung cancer, but was terminated after only one par…
Phase: PHASE1 • Sponsor: William Zeitler • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC